Lupus Nephritis Treatments
Find Lupus Nephritis Treatments
Brand Name
Saphnelo
Generic Name
Anifrolumab-fnia
View Brand Information FDA approval date: July 30, 2021
Classification: Type I Interferon Receptor Antagonist
Form: Injection
What is Saphnelo (Anifrolumab-fnia)?
SAPHNELO is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus , who are receiving standard therapy. Limitations of Use The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of SAPHNELO is not recommended in these situations. SAPHNELO is a type I interferon receptor antagonist indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus , who are receiving standard therapy. Limitations of Use: The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of SAPHNELO is not recommended in these situations.
Approved To Treat
Top Global Experts
There are no experts for this drug
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
PRESERVE: A Multi-Center Phase 4 Study of the Efficacy and Safety of LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab at Inducing Rapid Renal Response in Patients With Lupus Nephritis
Summary: The goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN).